

MEDIA RELEASE

19 May 2021

Pfizer Australia

Pfizer Australia Pty Limited
15-17, 151 Clarence St
Sydney NSW 2000
Australia

ABN 50 008 422 348

Pfizer Australia transitions to wholesaler distribution model

Pfizer Australia will distribute medicines through Community Service Obligation (CSO) pharmaceutical distribution, and transition from a direct distribution model to a wholesaler distribution model in the third quarter of 2021.

Pfizer announced the decision today by signing a contract with API and expects to finalise negotiations with other wholesalers shortly.

From the end of Q3 2021, Pfizer Australia will supply its portfolio of innovative and off-patent medicines to community and hospital pharmacies in Australia via the national wholesaler model.

Pfizer is one of the world's leading biopharmaceutical companies which in Australia supplies essential medicines and vaccines to more than 5,600 community pharmacies and their patients.

Pfizer Australia & New Zealand Managing Director Anne Harris said: "Pfizer has an increased focus on innovation and R&D as a biopharmaceutical business.

"Moving from direct to wholesale distribution will enable a greater focus on our core business as a biopharmaceutical company, and better position ourselves for growth.

"Pfizer's biopharma business has a diverse product portfolio and range of sales in Australia.

"Our wholesale model will not be exclusive to one wholesaler.

"We will continue to offer next business day delivery through wholesale distribution partners, to more than 5,600 pharmacies nationally, which is virtually all pharmacies in Australia", Ms Harris said.

"From now until late Q3 2021 it will be business as usual. Pfizer's existing logistics provider will transition out as a direct distribution partner, to our pre-wholesale partner, over the coming months.

"We are committed to ensuring that patients have access to our medicines and vaccines in every location in Australia, and our direct distribution model has been a key contributor to this.

"Pfizer would like to thank DHL for their strong partnership. They have had more than 10 years of success in the direct-to-market model servicing our patients.

"We have enjoyed a long and valued relationship with DHL and remain committed to working closely with them for a smooth transition from our direct distribution partnership and ensuring continued patient access to our medicines. We will continue to partner with DHL for our pre-wholesale activities," Ms Harris said.

ENDS

Media contact:

Helen Han
Corporate Affairs
Pfizer Australia
0466 641 224 | helen.han@pfizer.com

About Pfizer Australia: Breakthroughs that change patients' lives™

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines. Our diversified global health care portfolio includes biologic and small molecule medicines and vaccines, and many of the world's best-known consumer products.

Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked in countries around the world to make a difference for all who rely on us. For more information please visit: www.pfizer.com.au

